ROTTERDAM, Netherlands & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Harbour Antibodies BV today announced the signing of five new licenses to the company’s patented transgenic mouse platforms to discover next generation, high affinity, therapeutic human antibody products. These new licenses bring to 25 the total number of licenses by pharma and biotech companies, as well as academic organizations. The recent group of licensees includes MD Anderson Cancer Center and several international biotech companies and includes licenses to Harbour’s heavy chain only and conventional antibody generating transgenic mouse platforms.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
